Skip to main content

Table 2 Proportional hazards model for the development of hepatocellular carcinoma

From: Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C

 

Univariate analysis

Multivariate analysis

Factors

Hazards ratio (range)

p

Hazards ratio (range)

p

Age (years)

1.0 (0.99-1.1)

0.12

  

Sex (1: male)

5.6 (1.6-19)

0.0062

5.5 (1.5-21)

0.011

Body mass index

1.2 (1.0-1.3)

0.0086

1.2 (1.0-1.3)

0.029

Liver fibrosis

3.8 (1.9-7.3)

<0.0001

  

Hepatitis activity

1.1 (0.44-2.6)

0.88

  

Liver steatosis (>30%)

2.1 (0.95-4.8)

0.067

  

rs 8099917 of IL28B (TT)

0.62 (0.25-1.6)

0.31

  

rs 738409 of PNPLA3 (148 M)

0.40 (0.17-0.97)

0.043

  

Amino acid 70 of HCV core (glutamine)

3.4 (0.86-14)

0.082

  

Alanine aminotransferase (>40 IU/L)

1.2 (0.68-2.2)

0.51

  

Platelet count (104/mm3)

0.77 (0.69-0.87)

<0.0001

0.76 (0.66-0.88)

0.0002

Alpha fetoprotein (ng/mL)

1.1 (1.0-1.1)

0.0002

1.1 (1.0-1.1)

0.046

HOMA-IR

0.97 (0.79-1.2)

0.76

  

Sustained virological response

0.13 (0.03-0.57)

0.0067

  

Null or partial virological response

2.4 (1.0-5.9)

0.048

  
  1. : 95% confidence interval; PNPLA3, patatin-like phospholipase domain-containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance.